PepTcell Appoints Manfred Scheske as CEO of Consumer Health
Scheske, former President of Consumer Healthcare Europe at GlaxoSmithKline (“GSK”), is joining the Executive Team at PepTcell having enjoyed a highly successful 25-year career with GSK in Europe, North America and at a global level within GSK’s Consumer Healthcare Leadership Team.
Scheske, who was President of GSK’s £2 billion strong European Consumer Healthcare business from 2004 to 2010, also spent six years as President of GSK’s Consumer Healthcare business in North America. Amongst his successes was the launch of alli, GSK’s weight loss drug, which was the first pan-European switch from Rx to OTC. He built a market-leading position in the OTC smoking cessation market in the US and played a key role in the acquisition of Block Drug.
In his newly formed role at PepTcell, Scheske will have full responsibility for the consumer health portfolio. The leading products include a first-in-class cough suppressant with a clinically proven efficacy and safety profile. In addition, within the portfolio is a small molecule drug for inflammatory flare with a clinically proven safety analgesic profile entering Phase III trials.
PepTcell hosts a portfolio of innovative mid- to late stage drugs in development including vaccines, anti-inflammatory drugs, respiratory treatments, cancer treatments as well as metabolic disease medicines.
Commenting on today’s announcement, Gregory Stoloff, Chief Executive Officer of PepTcell, said: “We are delighted to have Manfred in our team. He is an extremely accomplished consumer healthcare professional whose superb industry knowledge and insight will be invaluable for guiding our ground-breaking consumer assets to market. Consumer health is an important part of our business and now a very exciting arena globally.”
Commenting on his appointment to the Executive team, Manfred Scheske, Chief Executive Officer, Consumer Health, at PepTcell, said: “I am very excited about joining PepTcell and look forward to applying my experience to our consumer health portfolio. PepTcell is uniquely positioned to bring breakthrough products to the two largest consumer health markets, which have not seen substantial innovation in decades.”
For more information about PepTcell, please contact:
PepTcell Limited Gregory Stoloff, Chief Executive Officer Tel +44 (0)20 7153 6570
M:Communications Mary-Jane Elliott / Amber Bielecka / Emma Thompson Tel +44 (0)20 7920 2330
About PepTcell
PepTcell is a privately held group with mid- to late stage high value products. Formed in 2004, the Company’s portfolio includes drugs in the following key areas: consumer health, immunotherapeutics, respiratory, vaccines and metabolic diseases. PepTcell has a universal flu vaccine and HIV vaccine in Phase Ib/II trials
PepTcell has a blue-chip management team and is well funded. The Company is headquartered in London, UK. For further information please visit the Company’s website at www.peptcell.com